{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:00:08Z","timestamp":1785276008240,"version":"3.55.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The diagnosis of bone metastases is an event with certain consequences for the patient. They often mean pain and can also mean pathological fractures, hypercalcemia, and spinal cord compression, all synonymous with a diminished quality of life and often also hospitalization. Since the advent of the intravenous bisphosphonates, things began to look a bit brighter for patients with bone metastases\u2014bone destruction was kept at bay a little longer. The next generation of bone metastasis treatments is well on its way in clinical development, and among them, the most advanced drug is denosumab. Denosumab is a fully human monoclonal antibody that inhibits osteoclast maturation, activation, and function by binding to receptor activator of nuclear factor kappa B ligand, with the final result being a reduced rate of bone resorption. In this review, we give an overview of relevant preclinical and clinical data regarding the use of denosumab in patients with solid tumors in general and prostate cancer in particular.<\/jats:p>","DOI":"10.1634\/theoncologist.2010-0154","type":"journal-article","created":{"date-parts":[[2011,2,2]],"date-time":"2011-02-02T04:05:31Z","timestamp":1296619531000},"page":"136-145","source":"Crossref","is-referenced-by-count":111,"title":["The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab"],"prefix":"10.1093","volume":"16","author":[{"given":"Daniel","family":"Castellano","sequence":"first","affiliation":[{"name":"a Medical Oncology Department, UroOncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"b Prostate Cancer Unit, UroOncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Sepulveda","sequence":"additional","affiliation":[{"name":"a Medical Oncology Department, UroOncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Garc\u00eda-Escobar","sequence":"additional","affiliation":[{"name":"a Medical Oncology Department, UroOncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Rodriguez-Antol\u00edn","sequence":"additional","affiliation":[{"name":"a Medical Oncology Department, UroOncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"b Prostate Cancer Unit, UroOncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sundl\u00f6v","sequence":"additional","affiliation":[{"name":"c Medical Oncology Department, Lund University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hern\u00e1n","family":"Cortes-Funes","sequence":"additional","affiliation":[{"name":"a Medical Oncology Department, UroOncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,2,1]]},"reference":[{"key":"2021122303220666000_B1","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"New Engl J Med"},{"key":"2021122303220666000_B2","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"New Engl J Med"},{"key":"2021122303220666000_B3","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0360-3016(93)90309-J","article-title":"Results of a randomized phase-iii trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer","volume":"25","author":"Porter","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122303220666000_B4","doi-asserted-by":"crossref","first-page":"8219","DOI":"10.1200\/JCO.2005.02.9579","article-title":"Bisphosphonates for treatment and prevention of bone metastases","volume":"23","author":"Michaelson","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122303220666000_B5","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2021122303220666000_B6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1006\/bbrc.1998.8586","article-title":"Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures","volume":"246","author":"Matsuzaki","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"2021122303220666000_B7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1083\/jcb.145.3.527","article-title":"The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts","volume":"145","author":"Burgess","year":"1999","journal-title":"J Cell Biol"},{"key":"2021122303220666000_B8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1006\/bbrc.2000.3129","article-title":"Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria","volume":"274","author":"O'Brien","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"2021122303220666000_B9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0002-9440(10)64556-7","article-title":"Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo","volume":"157","author":"Lacey","year":"2000","journal-title":"Am J Pathol"},{"key":"2021122303220666000_B10","doi-asserted-by":"crossref","first-page":"41155","DOI":"10.1074\/jbc.M506366200","article-title":"Functional dissection of osteoprotegerin and its interaction with receptor activator of nf-kappab ligand","volume":"280","author":"Schneeweis","year":"2005","journal-title":"J Biol Chem"},{"key":"2021122303220666000_B11","first-page":"4432","article-title":"Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis","volume":"61","author":"Morony","year":"2001","journal-title":"Cancer Res"},{"issue":"suppl 1","key":"2021122303220666000_B12","article-title":"RANK-L inhibition causes a greater suppression of tumor-induced osteoclastogenesis than zoledronate treatment in vivo and RANK-L rescues osteoclasts from zoledronate killing in vitro","volume":"21","author":"Tometsko","year":"2006","journal-title":"Am Soc Bone Miner Res"},{"key":"2021122303220666000_B13","first-page":"S147","article-title":"OPG inhibits the progression of bone destruction and skeletal tumor burden in mice with established osteolytic MDA-231 breast cancer metastases","volume":"17","author":"Morony","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2021122303220666000_B14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance t-cell growth and dendritic-cell function","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature"},{"key":"2021122303220666000_B15","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1210\/endo.142.4.8070","article-title":"Determination of three isoforms of the receptor activator of nuclear factor-\u03baB ligand and their differential expression in bone and thymus","volume":"142","author":"Ikeda","year":"2001","journal-title":"Endocrinology"},{"key":"2021122303220666000_B16","doi-asserted-by":"crossref","first-page":"36846","DOI":"10.1074\/jbc.M606656200","article-title":"Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of nf-kappab ligand","volume":"281","author":"Hikita","year":"2006","journal-title":"J Biol Chem"},{"key":"2021122303220666000_B17","first-page":"S380","article-title":"M-CSF independent mechanisms for osteoclastogenesis","volume":"22","author":"Nakamichi","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2021122303220666000_B18","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1084\/jem.188.5.997","article-title":"TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts","volume":"188","author":"Fuller","year":"1998","journal-title":"J Exp Med"},{"key":"2021122303220666000_B19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/46303","article-title":"Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand","volume":"402","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"2021122303220666000_B20","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1210\/endo.141.9.7634","article-title":"Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function","volume":"141","author":"Udagawa","year":"2000","journal-title":"Endocrinology"},{"key":"2021122303220666000_B21","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1210\/endo.139.10.6331","article-title":"A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro","volume":"139","author":"Quinn","year":"1998","journal-title":"Endocrinology"},{"key":"2021122303220666000_B22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"issue":"suppl 9","key":"2021122303220666000_B23","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2165","article-title":"Biology of RANK, RANK-L, and osteoprotegerin","volume":"1","author":"Boyce","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"2021122303220666000_B24","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1172\/JCI11685","article-title":"Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone","volume":"107","author":"Zhang","year":"2001","journal-title":"J Clin Invest"},{"issue":"suppl 12","key":"2021122303220666000_B25","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q","article-title":"The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma","volume":"88","author":"Carlin","year":"2000","journal-title":"Cancer"},{"key":"2021122303220666000_B26","first-page":"83","article-title":"Recent advances in bone biology provide insight into the pathogenesis of bone diseases","volume":"79","author":"Boyce","year":"1999","journal-title":"Lab Invest"},{"key":"2021122303220666000_B27","first-page":"2096","article-title":"Osteoprotegerin\/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic\/severe combined immunodeficient mice","volume":"63","author":"Yonou","year":"2003","journal-title":"Cancer Res"},{"key":"2021122303220666000_B28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molmed.2005.11.007","article-title":"RANK-L\u2013RANK signaling in osteoclastogenesis and bone disease","volume":"12","author":"Wada","year":"2006","journal-title":"Trends Mol Med"},{"key":"2021122303220666000_B29","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0090-4295(00)01122-5","article-title":"Osteoprotegerin and rank ligand expression in prostate cancer","volume":"57","author":"Brown","year":"2001","journal-title":"Urology"},{"key":"2021122303220666000_B30","first-page":"5438","article-title":"Receptor activator of nuclear factor-kappab ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo","volume":"63","author":"Farrugia","year":"2003","journal-title":"Cancer Res"},{"key":"2021122303220666000_B31","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature04524","article-title":"Regulation of cancer cell migration and bone metastasis by RANKL","volume":"440","author":"Jones","year":"2006","journal-title":"Nature"},{"key":"2021122303220666000_B32","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1210\/endo.140.10.7037","article-title":"Breast cancer cells interact with osteoblasts to support osteoclast formation","volume":"140","author":"Thomas","year":"1999","journal-title":"Endocrinology"},{"key":"2021122303220666000_B33","first-page":"2587","article-title":"Prostate cancer cells-osteoblast interaction shifts expression of growth\/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts","volume":"9","author":"Fizazi","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122303220666000_B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.cji.0000192105.24583.83","article-title":"Fully human therapeutic monoclonal antibodies","volume":"29","author":"Weiner","year":"2006","journal-title":"J Immunother"},{"key":"2021122303220666000_B35","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1172\/JCI11685","article-title":"Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone","volume":"107","author":"Zhang","year":"2001","journal-title":"J Clin Invest"},{"key":"2021122303220666000_B36","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1359\/jbmr.2003.18.5.852","article-title":"Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): A pharmacodynamic and pharmacokinetic analysis in rats","volume":"18","author":"Capparelli","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2021122303220666000_B37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/109158180302200512","article-title":"A toxicity profile of osteoprotegerin in the cynomolgus monkey","volume":"22","author":"Smith","year":"2003","journal-title":"Int J Toxicol"},{"key":"2021122303220666000_B38","first-page":"S29","article-title":"AMG 162, a fully human RANK-L antibody, increases bone mass and bone strength in cynomolgus monkeys","volume":"20","author":"Atkinson","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2021122303220666000_B39","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappab ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122303220666000_B40","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1349-7006.2008.00803.x","article-title":"Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases","volume":"99","author":"Yonemori","year":"2008","journal-title":"Cancer Sci"},{"key":"2021122303220666000_B41","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122303220666000_B42","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122303220666000_B43","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122303220666000_B44","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","article-title":"Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD","volume":"22","author":"Lewiecki","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2021122303220666000_B45","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"New Engl J Med"},{"key":"2021122303220666000_B46","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"New Engl J Med"},{"key":"2021122303220666000_B47","doi-asserted-by":"crossref","first-page":"18s","DOI":"10.1200\/jco.2010.28.18_suppl.lba4507","article-title":"A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer","volume":"28","author":"Fizazi","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122303220666000_B48","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/path.1199","article-title":"RANK ligand is a prerequisite for cancer-associated osteolytic lesions","volume":"198","author":"Kitazawa","year":"2002","journal-title":"J Pathol"},{"key":"2021122303220666000_B49","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1210\/endo.140.10.7037","article-title":"Breast cancer cells interact with osteoblasts to support osteoclast formation","volume":"140","author":"Thomas","year":"1999","journal-title":"Endocrinology"},{"key":"2021122303220666000_B50","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0002-9440(10)63560-2","article-title":"Receptor activator of nuclear factor kappab ligand (RANK-L)\/osteoprotegerin (OPG) ratio is increased in severe osteolysis","volume":"163","author":"Grimaud","year":"2003","journal-title":"Am J Pathol"},{"key":"2021122303220666000_B51","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122303220666000_B52","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1359-6349(09)72028-2","article-title":"Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: Results of a randomized phase 3 study","volume":"7","author":"Stopeck","year":"2009","journal-title":"Eur J Cancer Suppl"},{"key":"2021122303220666000_B53","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: A population-based study","volume":"20","author":"Melton","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2021122303220666000_B54","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3109\/10428190309178765","article-title":"New insights in myeloma-induced osteolysis","volume":"44","author":"Barill\u00e9-Nion","year":"2003","journal-title":"Leukemia Lymphoma"},{"key":"2021122303220666000_B55","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.exphem.2004.03.015","article-title":"New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of nf-kappab ligand (RANK-L)","volume":"32","author":"Giuliani","year":"2004","journal-title":"Exp Hematol"},{"key":"2021122303220666000_B56","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble wnt inhibitor, sfrp-2","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"key":"2021122303220666000_B57","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"2021122303220666000_B58","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.21509","article-title":"An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma","volume":"84","author":"Vij","year":"2009","journal-title":"Am J Hematol"},{"key":"2021122303220666000_B59","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1359-6349(09)72055-5","article-title":"A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"7","author":"Henry","year":"2009","journal-title":"Eur J Cancer Suppl"},{"key":"2021122303220666000_B60","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.9133","article-title":"Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer","volume":"28","author":"Henry","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122303220666000_B61","author":"Background Document for Meeting of Advisory Committee for Reproductive Health Drugs","year":"2009"},{"key":"2021122303220666000_B62","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.bone.2010.10.048","article-title":"Incidence and outcomes of osteonecrosis of the jaw from an integrated analysis of three pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab and zoledronic acid for treatment of bone metastases in advanced cancer patients or myeloma","volume":"48","author":"Brown","year":"2011","journal-title":"Bone"},{"issue":"suppl 12","key":"2021122303220666000_B63","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1002\/1097-0142(20000615)88:12+<3033::AID-CNCR20>3.0.CO;2-C","article-title":"Bisphosphonates and breast carcinoma: present and future","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2010-0154","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2010-0154","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/2\/136\/41852987\/oncolo_16_2_136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/2\/136\/41852987\/oncolo_16_2_136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T04:39:27Z","timestamp":1640234367000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/16\/2\/136\/6400741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,1]]},"references-count":63,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2011,2,1]]},"published-print":{"date-parts":[[2011,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2010-0154","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,2,1]]},"published":{"date-parts":[[2011,2,1]]}}}